325 related articles for article (PubMed ID: 24102067)
1. Data-mining for sulfur and fluorine: an evaluation of pharmaceuticals to reveal opportunities for drug design and discovery.
Ilardi EA; Vitaku E; Njardarson JT
J Med Chem; 2014 Apr; 57(7):2832-42. PubMed ID: 24102067
[TBL] [Abstract][Full Text] [Related]
2. Beyond C, H, O, and N! Analysis of the elemental composition of U.S. FDA approved drug architectures.
Smith BR; Eastman CM; Njardarson JT
J Med Chem; 2014 Dec; 57(23):9764-73. PubMed ID: 25255063
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical structure montages as catalysts for design and discovery.
Njarðarson JT
Future Med Chem; 2012 May; 4(8):951-4. PubMed ID: 22650237
[TBL] [Abstract][Full Text] [Related]
4. Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023.
Ali S; Bolinger AA; Zhou J
Curr Top Med Chem; 2024; 24(10):843-849. PubMed ID: 38445700
[TBL] [Abstract][Full Text] [Related]
5. Analysis of US FDA-Approved Drugs Containing Sulfur Atoms.
Scott KA; Njardarson JT
Top Curr Chem (Cham); 2018 Jan; 376(1):5. PubMed ID: 29356979
[TBL] [Abstract][Full Text] [Related]
6. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
7. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
8. Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).
Ali S; Zhou J
Eur J Med Chem; 2023 Aug; 256():115476. PubMed ID: 37207534
[TBL] [Abstract][Full Text] [Related]
9. Practical synthesis of fluorine-containing α- and β-amino acids: recipes from Kiev, Ukraine.
Kukhar VP; Sorochinsky AE; Soloshonok VA
Future Med Chem; 2009 Aug; 1(5):793-819. PubMed ID: 21426081
[TBL] [Abstract][Full Text] [Related]
10. How drugs are developed and approved by the FDA: current process and future directions.
Ciociola AA; Cohen LB; Kulkarni P;
Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
[TBL] [Abstract][Full Text] [Related]
11. Regulatory advice and drug development--a case study in negotiating with regulators.
Seldrup J
Stat Med; 2011 Jun; 30(13):1628-35. PubMed ID: 21365671
[TBL] [Abstract][Full Text] [Related]
12. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
13. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
14. FDA policy on unapproved drug products: past, present, and future.
Chhabra R; Kremzner ME; Kiliany BJ
Ann Pharmacother; 2005; 39(7-8):1260-4. PubMed ID: 15956239
[TBL] [Abstract][Full Text] [Related]
15. What's next after 50 years of psychiatric drug development: an FDA perspective.
Laughren TP
J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
[TBL] [Abstract][Full Text] [Related]
16. Adverse effects in women: implications for drug development and regulatory policies.
Parekh A; Fadiran EO; Uhl K; Throckmorton DC
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):453-66. PubMed ID: 22114855
[TBL] [Abstract][Full Text] [Related]
17. Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019.
Yin Z; Hu W; Zhang W; Konno H; Moriwaki H; Izawa K; Han J; Soloshonok VA
Amino Acids; 2020 Sep; 52(9):1227-1261. PubMed ID: 32880009
[TBL] [Abstract][Full Text] [Related]
18. Fluorine in pharmaceutical industry: fluorine-containing drugs introduced to the market in the last decade (2001-2011).
Wang J; Sánchez-Roselló M; Aceña JL; del Pozo C; Sorochinsky AE; Fustero S; Soloshonok VA; Liu H
Chem Rev; 2014 Feb; 114(4):2432-506. PubMed ID: 24299176
[No Abstract] [Full Text] [Related]
19. International Conference on Harmonisation; addendum to International Conference on Harmonisation Guidance on S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2012 May; 77(97):29665-6. PubMed ID: 22616137
[TBL] [Abstract][Full Text] [Related]
20. What's in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications.
Serafini M; Cargnin S; Massarotti A; Tron GC; Pirali T; Genazzani AA
J Med Chem; 2021 Apr; 64(8):4410-4429. PubMed ID: 33847110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
